---
title: "AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Economic burden and healthcare resource utilization"
description: "Formulary evidence on AD109 (aroxybutynin-atomoxetine, Oxnimbi) in Obstructive sleep apnea: Economic burden and healthcare resource utilization. Topics: Estimated U.S. societal cost of undiagnosed obstructive sleep apnea in 2015; Workplace productivity loss attributed to obstructive sleep apnoea syndrome in the USA; Medicare beneficiaries: health care use and costs in the year before obstructive sleep apnea treatment; Medical costs in the year before diagnosis of sleep apnea, single health plan; 6 further topics. 10 evidence topics quoted from 10 sources."
canonical: "https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description/economic-burden-and-healthcare-resource-utilization"
published: "2026-11-18T10:43:47-05:00"
modified: "2026-11-18T10:43:47-05:00"
---

# AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Economic burden and healthcare resource utilization

<a id="heading-2.2.1.8.2"></a>

## 2.2.1.8.2 Economic Burden and Healthcare Resource Utilization

<a id="topic-2.2.1.8.2-1"></a>

### Estimated U.S. societal cost of undiagnosed obstructive sleep apnea in 2015

> “Frost & Sullivan estimates that undiagnosed OSA cost the United States approximately $149.6 billion in 2015.”
> “When calculating the respective costs for leaving OSA undiagnosed versus diagnosing and treating it, financial modeling indicates that treatment costs are approximately 33% of non-treatment costs”
> “Frost & Sullivan estimates that untreated OSA in the United States resulted in a loss of productivity estimated at $86.9 billion in 2015.”
> “The total economic impact of all motor vehicle accidents in the United States where undiagnosed OSA was a contributing factor was estimated at $26.2 billion in 2015.”
> “Costs for these accidents due to undiagnosed and untreated OSA totaled $6.5 billion in 2015.”

Source: [Frost & Sullivan (2016)](https://aasm.org/resources/pdf/sleep-apnea-economic-crisis.pdf)

<a id="topic-2.2.1.8.2-2"></a>

### Workplace productivity loss attributed to obstructive sleep apnoea syndrome in the USA

> “This study estimates the prevalence and workplace productivity burden of obstructive sleep apnoea (OSA) syndrome in the UK and USA, using self-reported breathing pauses and excessive daytime sleepiness as a proxy.”
> “Annual productivity losses were estimated at US$180.2 billion in the USA and £4.22 billion in the UK. In the UK and USA, individual-level productivity losses exceeded the cost of continuous positive airway pressure (CPAP) treatment”

Source: [Rehman et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41735061/)

<a id="topic-2.2.1.8.2-3"></a>

### Medicare beneficiaries: health care use and costs in the year before obstructive sleep apnea treatment

> “The final sample (n = 287,191) included 10,317 beneficiaries with OSA and 276,874 control patients. In fully adjusted models, during the year prior to OSA diagnosis and relative to matched control patients, beneficiaries with OSA demonstrated increased HCU and higher mean total annual costs ($19,566, 95% confidence interval [CI] $13,239, $25,894) as well as higher mean annual costs across all individual points of service.”
> “Inpatient care was associated with the highest incremental costs (ie, greater than control patients; $15,482, 95% CI $8,521, $22,443) and prescriptions were associated with the lowest incremental costs (ie, greater than control patients; $431, 95% CI $339, $522).”

Source: [Wickwire et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7053009/)

<a id="topic-2.2.1.8.2-4"></a>

### Medical costs in the year before diagnosis of sleep apnea, single health plan

> “Among cases, mean annual medical cost prior to diagnosis was $2720 versus $1384 for age and gender matched controls (p<0.01).”
> “Using available data on the prevalence of undiagnosed moderate to severe sleep apnea in middle-aged adults, we estimate that untreated sleep apnea may cause $3.4 billion in additional medical costs in the U.S.”

Source: [Kapur et al. (1999)](https://pubmed.ncbi.nlm.nih.gov/10505820/)

<a id="topic-2.2.1.8.2-5"></a>

### Positive airway pressure adherence and health care use and costs in obstructive sleep apnea with obesity, ResMed-funded claims analysis

> “Among 173,691 patients, 35.2% were adherent, 39.1% intermediately adherent, and 25.7% nonadherent. After applying inverse probability of treatment weighting (IPTW), in year 1 post-index, adherent patients had significantly fewer ER visits and hospitalizations (0.55 ± 1.77 and 0.10 ± 0.44) compared to nonadherent patients (0.69 ± 1.78 and 0.14 ± 0.56; P < 0.001), and significantly lower total healthcare costs (11,332 ± 21,160 vs 11,927 ± 20,212; P < 0.001).”
> “This study was funded by Resmed.”

Source: [Sert Kuniyoshi et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13056527/)

<a id="topic-2.2.1.8.2-6"></a>

### Positive airway pressure adherence and health care use in comorbid insomnia and obstructive sleep apnea, ResMed-funded claims analysis

> “From a sample of 27,071 patients with COMISA (average age, 53.6 years; 53% female), 72% were at least intermediately adherent to PAP over 2 years.”
> “When viewed in the context of patients with OSA without insomnia, patients with COMISA showed lower PAP use and higher rates of resource use both before and after the index date, but showed similar relative reductions in ER visits and hospitalizations with PAP adherence.”
> “This study was funded by ResMed.”

Source: [Cole et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12720397/)

<a id="topic-2.2.1.8.2-7"></a>

### CPAP adherence and inpatient use in Medicare beneficiaries with cardiovascular disease

> “After adjusting for covariates and relative to low adherers, high adherers demonstrated reduced inpatient visits (hazard ratio 0.75; 95% confidence interval 0.57, 0.97).”

Source: [Wickwire et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8807906/)

<a id="topic-2.2.1.8.2-8"></a>

### CPAP adherence and 30-day readmission in Medicare beneficiaries with cardiovascular disease

> “Among 1,301 beneficiaries meeting study criteria, the 30-day readmission rate was 10.2%. In adjusted models and compared to patients with low CPAP adherence, those with high adherence had lower odds of 30-day readmission (odds ratio 0.41; 95% confidence interval 0.24–0.70).”

Source: [Bailey et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9713924/)

<a id="topic-2.2.1.8.2-9"></a>

### CPAP termination and permanent work disability in the French national claims database

> “The analysis included 174,270 individuals (median age, 52.0 yr [interquartile range, 44.0–57.0 yr]; 67.5% male). The 1-year CPAP therapy termination rate was 22.3%.”
> “In an adjusted multivariable Cox model, CPAP termination was associated with an increased risk of permanent work disability (hazard ratio, 1.21; 95% confidence interval [CI], 1.04–1.41; P = 0.01), primarily in the subgroup aged >55 years (hazard ratio, 1.41; 95% CI, 1.06–1.87; P = 0.02).”

Source: [Bailly et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12039934/)

<a id="topic-2.2.1.8.2-10"></a>

### Societal cost-of-illness estimate for Italy from a systematic review

> “Twenty-six clinical (e.g., diabetes) and non-clinical (e.g., car accidents) conditions were found to be significantly influenced by OSA, contributing to an economic burden ranging from €10.7 to €32.0 billion/year in Italy. The cost of impaired quality of life due to OSA undertreatment is between €2.8 and €9.0 billion/year. These costs are substantially higher than those currently borne to diagnose and treat OSA (€234 million/year).”

Source: [Borsoi et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9122203/)

## Related pages
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Terms and abbreviations](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations.md)
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Product information and disease description](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Clinical evidence](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Economic information and modeling report](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: References](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references.md)
